Arrowhead completes enrollment in Phase 3 HoFH drug trial

July 27, 2026 7:30 AM

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has completed enrollment in its global Phase 3 YOSEMITE clinical trial of zodasiran, an investigational RNA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found